Stimalia develops the first bioelectronic medical device for PTSD, transforming trauma care through minimally invasive neuromodulation that directly addresses the body's dysregulated stress response. The Crisis PTSD affects 24 million adults across Europe and the US, costing €350 billion annually. Over 50% remain symptomatic despite current therapies. Medications cause systemic side effects. Psychotherapy is time-intensive. Nerve blocks fade within weeks. Patients suffer persistent disability, opioid dependence, and elevated suicide risk. Our Innovation We've engineered a revolutionary grain-of-rice-sized, battery-free percutaneous bioelectronic implant. Wirelessly activated, it delivers sustained inhibition of pathological sympathetic hyperactivity, the nervous system overdrive driving PTSD symptoms. Unlike temporary nerve blocks, our approach provides continuous, adjustable, fully reversible therapy without surgery, leads, or systemic side effects.
Something looks off?On-site & Remote